Swiss National Bank Has $508.28 Million Stake in Pfizer Inc. (NYSE:PFE)

Swiss National Bank cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,654,712 shares of the biopharmaceutical company’s stock after selling 503,300 shares during the quarter. Swiss National Bank owned approximately 0.31% of Pfizer worth $508,279,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in PFE. Trifecta Capital Advisors LLC increased its position in shares of Pfizer by 3.7% during the third quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 325 shares during the period. Confluence Wealth Services Inc. grew its holdings in Pfizer by 0.5% during the 3rd quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock worth $2,158,000 after acquiring an additional 342 shares during the period. Carr Financial Group Corp raised its position in shares of Pfizer by 3.3% in the 3rd quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock worth $344,000 after acquiring an additional 355 shares in the last quarter. Caldwell Sutter Capital Inc. lifted its stake in shares of Pfizer by 0.5% in the 3rd quarter. Caldwell Sutter Capital Inc. now owns 69,794 shares of the biopharmaceutical company’s stock valued at $2,315,000 after purchasing an additional 364 shares during the period. Finally, Lafayette Investments Inc. boosted its position in shares of Pfizer by 2.2% during the 3rd quarter. Lafayette Investments Inc. now owns 17,470 shares of the biopharmaceutical company’s stock valued at $579,000 after purchasing an additional 368 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on PFE. Morgan Stanley lifted their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $36.00.

Pfizer Stock Performance

Shares of PFE stock traded up $0.68 during trading hours on Thursday, hitting $27.86. 36,395,305 shares of the company were exchanged, compared to its average volume of 42,519,922. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $157.76 billion, a price-to-earnings ratio of 77.25, a P/E/G ratio of 1.15 and a beta of 0.63. The firm has a fifty day simple moving average of $26.87 and a 200 day simple moving average of $28.25. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period last year, the business posted $1.23 earnings per share. Research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.03%. Pfizer’s payout ratio is 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.